The APP of Zhitong Finance has learned that TD Cowen, an investment agency, has recently contacted$Moderna (MRNA.US)$At a formal meeting with management, Moderna Inc provided important details of his COVID-19 vaccine sales prospects in 2023, as well as product planning in addition to COVID-19 vaccine, and said that from a long-term point of view, the market may need influenza vaccine with mRNA technology route.
Moderna Inc said that the flu vaccine market in 2024 may usher in the company's new products. In addition, the company said that mRNA-1345, which is under development, will be a key player in the important market of RSV, while personalized cancer vaccines (PCV) represent a broad market opportunity, which may face significant opportunities in the field of rare diseases in the next five years. Cowen, on the other hand, continues to maintain its "in line with the market" rating of Moderna Inc's stock and its target share price of $150.